MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4), also known as MKK4 or JNKK1, is a dual-specificity protein kinase that serves as a critical node in cellular stress signaling. It phosphorylates and activates both the JNK (c-Jun N-terminal kinase) and p38 MAPK pathways, making it a central regulator of stress responses, apoptosis, and cell survival in the brain.
| MAP2K4 Gene |
|---|
| Gene Symbol | MAP2K4 |
| Alternative Names | MKK4, JNKK1, MEK4, SKK4 |
| Full Name | Mitogen-Activated Protein Kinase Kinase 4 |
| Chromosomal Location | 17p12 |
| NCBI Gene ID | [5606](https://www.ncbi.nlm.nih.gov/gene/5606) |
| UniProt ID | [P45985](https://www.uniprot.org/uniprot/P45985) |
| Ensembl ID | ENSG00000157873 |
| Protein Size | 399 amino acids |
¶ Protein Structure and Function
¶ Kinase Domain Architecture
MAP2K4 contains:
- N-terminal docking domain: For interaction with substrates and upstream kinases
- Kinase domain: Catalytic core with dual-specificity
- C-terminal regulatory region: Contains serine/threonine residues for activation
As a dual-specificity kinase, MAP2K4:
| Substrate |
Activation Site |
Downstream Effect |
| JNK1/2/3 |
Thr183/Tyr185 |
AP-1 activation, apoptosis |
| p38α/β |
Thr180/Tyr182 |
Inflammation, stress response |
MAP2K4 is activated by:
- MAP3K phosphorylation: MEKK1-4, MLK3, TAK1, TAOK1/2/3
- Dual phosphorylation: On S/T-Y residues in the activation loop
- JNK-specific activation: Can be regulated by scaffold proteins
The MAP2K4 protein contains several key structural features:
- N-terminal D-domain: Conserved docking motif for interaction with upstream MAP3Ks and downstream MAPK substrates
- Kinase domain (aa 80-330): Contains the catalytic core with the dual-specificity activity
- Activation loop: Contains the critical S222 and S228 phosphorylation sites
- C-terminal regulatory region: Modulates interaction with scaffolds and localization
flowchart TD
A["Stress Signals"] --> B["UV Radiation"]
A --> C["Oxidative Stress"]
A --> D["Pro-inflammatory Cytokines"]
A --> E["Excitotoxicity"]
B --> F["MAP3K Activation"]
C --> F
D --> F
E --> F
F --> G["MAP2K4 Activation"]
G --> H["JNK Activation"]
G --> I["p38 Activation"]
H --> J["Transcription Factor Phosphorylation"]
I --> J
J --> K["Gene Expression Changes"]
K --> L["Apoptosis / Survival / Inflammation"]
style L fill:#ffcdd2,stroke:#333
| Function |
Pathway |
Outcome |
| Stress Response |
p38 |
Cytokine production, cell adaptation |
| Apoptosis |
JNK |
Pro-apoptotic signaling in neurons |
| Inflammation |
p38 |
Neuroinflammatory responses |
| Synaptic Plasticity |
JNK |
Excitotoxicity, memory impairment |
- Hippocampus: High expression in CA1-CA3 and dentate gyrus
- Cortex: All layers, particularly layers II-III and V
- Cerebellum: Purkinje cells and granule cells
- Substantia Nigra: Dopaminergic neurons
- Neurons: Cytoplasmic and nuclear compartments
- Astrocytes: Induced under stress conditions
- Microglia: Activated state expression
In Alzheimer's disease:
- JNK Activation: Correlates with tau pathology and neurofibrillary tangle formation
- Amyloid-β Effects: Aβ oligomers activate MAP2K4/JNK pathway
- Synaptic Dysfunction: JNK-mediated phosphorylation of synaptic proteins
- Neuronal Apoptosis: MAP2K4 contributes to Aβ-induced neuronal death
In Parkinson's disease:
- Dopaminergic Vulnerability: MAP2K4/JNK pathway activated in substantia nigra neurons
- Mitochondrial Toxins: MPTP, 6-OHDA activate JNK pathway
- α-Synuclein Pathology: Aggregation triggers MAP2K4 signaling
- Neuroprotection: JNK inhibitors protect dopaminergic neurons
- Motor Neuron Degeneration: MAP2K4/JNK pathway activated in ALS models
- Excitotoxicity: Contributes to glutamate-induced motor neuron death
- Therapeutic Target: JNK inhibitors show promise in preclinical models
¶ Stroke and Brain Injury
- Ischemic Damage: Strong activation of JNK pathway following stroke
- Neuroprotection: MAP2K4 inhibition reduces infarct size in models
- Therapeutic Window: Potential for intervention post-stroke
| Approach |
Status |
Target |
| JNK Inhibitors |
Clinical trials |
c-Jun, JNK pathway |
| p38 Inhibitors |
Clinical trials |
Inflammatory responses |
| MAP2K4 Modulators |
Preclinical |
Pathway activation |
- Phospho-JNK levels: Potential marker for neuronal stress
- MAP2K4 activity: Could indicate disease progression
- Brain-penetrant JNK inhibitors: For neurodegenerative diseases
- Combination therapies: With antioxidants or neuroprotective agents
- Gene therapy: Targeting upstream activators
| Interactor |
Type |
Relationship |
| MAP3K1-4 |
Kinase |
Upstream activators |
| JNK1/2/3 |
Kinase |
Substrate |
| p38α/β |
Kinase |
Substrate |
| JIP1/2/3 |
Scaffold |
Localization |
| ATF2 |
Transcription factor |
Downstream target |
MAP2K4 exhibits differential activation of MAPK isoforms:
| MAP2K4 Activity |
JNK Isoforms |
p38 Isoforms |
Physiological Outcome |
| High |
JNK1/JNK2 |
p38α |
Strong pro-apoptotic signaling |
| Moderate |
JNK3 |
p38β |
Tissue-specific effects |
| Low |
JNK1/2 |
p38γ/δ |
Stress adaptation |
MAP2K4 activity is negatively regulated by:
- MAPK phosphatases (MKPs): DUSP1, DUSP2, DUSP10 dephosphorylate MAP2K4
- Inhibitory phosphorylation: Serine/threonine phosphatases reverse activation
- Protein inhibitors: Specific protein inhibitors of MAP2K4
| Approach |
Status |
Target |
| JNK Inhibitors |
Clinical trials |
c-Jun, JNK pathway |
| p38 Inhibitors |
Clinical trials |
Inflammatory responses |
| MAP2K4 Modulators |
Preclinical |
Pathway activation |
| Dual JNK/p38 Inhibitors |
Preclinical |
Broader pathway inhibition |
- Phospho-JNK levels: Potential marker for neuronal stress
- MAP2K4 activity: Could indicate disease progression
- Phospho-p38: Inflammatory biomarker
- Brain-penetrant JNK inhibitors: For neurodegenerative diseases
- Combination therapies: With antioxidants or neuroprotective agents
- Gene therapy: Targeting upstream activators
- Scaffold disruptors: Blocking pathological MAP2K4 interactions